Skip to main navigation Skip to search Skip to main content

Recurrent amplification at 7q21.2 targets CDK6 gene in primary myxofibrosarcomas and identifies CDK6 overexpression as an independent adverse prognosticator

  • Jen Wei Tsai*
  • , Chien Feng Li
  • , Yu Chien Kao
  • , Jun Wen Wang
  • , Fu Min Fang
  • , Yu Hui Wang
  • , Wen Ren Wu
  • , Li Ching Wu
  • , Chung Hsi Hsing
  • , Shau Hsuan Li
  • , Shih Chen Yu
  • , Jui Lan
  • , Hsuan Ying Huang
  • *Corresponding author for this work
  • E-Da Hospital
  • Chi-Mei Medical Center
  • National Sun Yat-sen University
  • National Cheng Kung University
  • Southern Taiwan University of Science and Technology
  • Taipei Medical University
  • Chang Gung University

Research output: Contribution to journal › Journal Article › peer-review

26 Scopus citations

Abstract

Background: Myxofibrosarcoma is genetically complex and remains obscure in molecular determinants of clinical aggressiveness. Our prior study revealed recurrent gains of 7q in myxofibrosarcomas where MET and CDK6 genes displayed increased DNA copies. Previously, we demonstrated the implication of MET overexpression, prompting us to further elucidate the roles of CDK6 in myxofibrosarcomas. Materials: On tissue microarrays, CDK6 immunoexpression was assessable in 77 primary tumors, 55 of which were successfully quantified for CDK6 and MET genes by real-time PCR using genomic DNA extracted from laser-microdissected tumor cells. Gene status and protein expression of CDK6 were correlated with each other, clinicopathological variables, metastasis-free survival (MFS), and disease-specific survival (DSS). Results: Protein overexpression and gene amplification of CDK6, which were detected in 21 of 77 (27.2 %) and 13 of 55 cases (23.6 %), respectively, were highly related to each other (p < .001) and associated with higher grades (overexpression, p = .004; amplification, p = .014). There was a strong correlation between CDK6 and MET gene copies (p < .001, r = 0.0714). Importantly, CDK6 protein overexpression (MFS, p = .0002; DSS, p = .0015) and gene amplification (MFS, p = .0001; DSS, p = .0083) were both univariately associated with worse outcomes. Together with nonextremity location and AJCC stage III disease, CDK6 overexpression independently portended inferior MFS (p = .0015, risk ratio [RR] = 7.411). This aberration, along with nonextremity location, was also an independent adverse prognosticator of DSS (p = .0069, RR = 6.006). Conclusions: In approximately a quarter of primary myxofibrosarcomas, CDK6 overexpression is mostly driven by gene amplification on 7q, associated with adverse prognosticators, and independently predictive of worse outcomes, highlighting its possible causative role in tumor aggressiveness.

Original languageEnglish
Pages (from-to)2716-2725
Number of pages10
JournalAnnals of Surgical Oncology
Volume19
Issue number8
DOIs
StatePublished - 08 2012
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Recurrent amplification at 7q21.2 targets CDK6 gene in primary myxofibrosarcomas and identifies CDK6 overexpression as an independent adverse prognosticator'. Together they form a unique fingerprint.

Cite this